These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36225746)

  • 1. Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine.
    Zhang A; Johnson T; Abbott D; Phupitakphol T; Gutman JA; Pollyea DA; Koullias Y
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac486. PubMed ID: 36225746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia.
    Wang ST; Chou CH; Chen TT; Lin CC; Bai LY; Yeh SP; Ho MW; Lien MY
    Front Cell Infect Microbiol; 2022; 12():1012334. PubMed ID: 36530436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short-term Effect of Venetoclax Combined with Azacitidine and "7+3" Regimen in the Treatment of Newly Diagnosed Elder Patients with Acute Myeloid Leukemia].
    Liu XX; Wen XL; Li RQ; Zhang XL; Zhang TB; Dong CX; Wang MF; Zhang JH; Yang LH; Zhang RJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):96-103. PubMed ID: 38387906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
    Chen EC; Liu Y; Harris CE; Winer ES; Wadleigh M; Lane AA; Vedula RS; Lindsley RC; Copson KM; Charles A; Marty F; Neuberg D; DeAngelo DJ; Stone RM; Luskin MR; Issa NC; Garcia JS
    Leuk Lymphoma; 2022 Aug; 63(8):1934-1941. PubMed ID: 35289704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 6. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Models for Long Term Survival of AML Patients Treated with Venetoclax and Azacitidine or 7+3 Based on Post Treatment Events and Responses: Retrospective Cohort Study.
    Islam N; Reuben JS; Dale J; Coates JW; Sapiah K; Markson FR; Jordan CT; Smith C
    JMIR Cancer; 2024 Aug; 10():e54740. PubMed ID: 39167784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
    Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
    Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
    Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
    Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
    Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
    Aldoss I; Dadwal S; Zhang J; Tegtmeier B; Mei M; Arslan S; Al Malki MM; Salhotra A; Ali H; Aribi A; Sandhu K; Khaled S; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Blood Adv; 2019 Dec; 3(23):4043-4049. PubMed ID: 31816059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
    Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR
    Front Oncol; 2022; 12():858202. PubMed ID: 35433414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
    On S; Rath CG; Lan M; Wu B; Lau KM; Cheung E; Alegria W; Young R; Tan M; Kim C; Phun J; Patel N; Mannis G; Logan AC; Kennedy V; Goodman A; Taplitz RA; Young PA; Wen R; Saunders IM
    Br J Haematol; 2022 Apr; 197(1):63-70. PubMed ID: 35174480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis.
    Sezgin Evim M; Tüfekçi Ö; Baytan B; Ören H; Çelebi S; Ener B; Üstün Elmas K; Yılmaz Ş; Erdem M; Hacımustafaoğlu MK; Güneş AM
    Turk J Haematol; 2022 Jun; 39(2):94-102. PubMed ID: 34792308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.
    Ravindran M; Mozessohn L; Cheung M; Buckstein R; Teichman J
    Blood Adv; 2024 Feb; 8(3):629-639. PubMed ID: 38029373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive Fungal Infections in Children With Acute Myeloid Leukemia: A Single-center Experience Over 19 Years.
    Avcu G; Karadas N; Goktepe SO; Bal ZS; Metin DY; Polat SH; Aydinok Y; Karapinar DY
    J Pediatr Hematol Oncol; 2023 Oct; 45(7):392-397. PubMed ID: 37526370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
    Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y
    Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia].
    Gong BF; Liu YT; Zhang GJ; Wei SN; Li Y; Liu KQ; Gong XY; Zhao XL; Qiu SW; Gu RX; Lin D; Wei H; Zhou CL; Liu BC; Wang Y; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):528-531. PubMed ID: 28655098
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
    Kim GYG; Burns J; Freyer CW; Hamilton KW; Frey NV; Gill SI; Hexner EO; Luger SM; Mangan JK; Martin ME; McCurdy SR; Perl AE; Porter DL; Schuster MG; Stadtmauer EA; Loren AW
    Am J Hematol; 2020 Jul; 95(7):792-798. PubMed ID: 32242967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.